跳至主要内容
临床试验/ITMCTR2023000032
ITMCTR2023000032招募中Unknown

Efficacy and safety of Fuzheng Kangai granule combined with immune checkpoint inhitbitor for advanced non-small cell lung cancer: a randomized, double-blind, placebo-controlled trial

Guangdong Provincial Hospital of Chinese Medicine0 个研究点开始时间: 待定最近更新:
适应症

试验速览

阶段
Unknown
状态
招募中
发起方

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
18 至 80(—)
性别
All

入选标准

  • (a) Patients who were confirmed advanced primary NSCLC (stage IIIb, IIIc, IVa, or IVb) by histology or cytology according to the 8th TNM classification of lung cancer without gene mutation and with positive PD-L1 expression; (b) Age from 18 to 80 years; (d) Life expectancy over 3 months; (e) Existing at least one measurable lesion; (f) Eastern Cooperative Oncology Group (ECOG) performance status less than 2 scores; (g) Meeting the indication of using PD-1 inhibitor; (h) Signing informed consent and participating in the study voluntarily.

排除标准

  • (a) Participating in another interventional clinical study currently or within 4 weeks; (b) Prior immunotherapy; (c) Performing a major surgery within 3 weeks; (d) Using a long-term systemic corticosteroid; (e) Severe infection using antibiotics; (f) Dysphagia; (g) An active autoimmune disease requiring systemic treatment occurred within 2 years; (h) Currently pregnant or breastfeeding; (i) Symptomatic central nervous system metastases.

研究者

发起方
Guangdong Provincial Hospital of Chinese Medicine

相似试验